期刊文献+

链霉菌CPCC 203702中抗结核分枝杆菌活性次级代谢产物的分离与鉴定

Isolation and identification of anti-Mycobacterium tuberculosis secondary metabolites from Streptomyces sp. CPCC 203702
下载PDF
导出
摘要 目的研究链霉菌CPCC 203702中的抗结核分枝杆菌活性次级代谢产物。方法发酵液离心后,上清液经乙酸乙酯萃取、正相硅胶柱色谱、Sephadex LH-20凝胶柱色谱和半制备HPLC等方法进行以抗耻垢分枝杆菌活性为导向的活性化合物分离纯化,通过质谱和核磁共振波谱技术并结合文献数据进行化合物结构鉴定;分别采用平板纸片法和阿尔玛蓝法检测目的化合物的抗耻垢分枝杆菌以及抗结核分枝杆菌活性。结果从链霉菌CPCC 203702发酵液中分离到1个具有显著的抗结核分枝杆菌活性的伯尔尼霉素类化合物伯尔尼霉素C,其抗结核分枝杆菌MIC为2μg/ml;完成其核磁数据的完整归属。结论首次报道了伯尔尼霉素类抗生素具有显著的抗结核分枝杆菌活性,丰富了硫肽类抗生素的活性研究,也为抗结核药物的发现提供一个新的视角。 Objective To investigate isolation and identification of anti-Mycobacterium tuberculosis secondary metabolites from Streptomyces sp. CPCC 203702.Methods The fermentation culture was separated into the supernatant and mycelia by using low-speed centrifugation. The supernatant was extracted with EtOAc, and the EtOAc extract was isolated and purified by combined use of silica gel column chromatography, Sephadex LH-20 colunm chromatography and semi-preparative HPLC. The anti-Mycobacterium tuberculosis activity was tested by MABA method. The structure of isolated pure compound was elucidated by extensive spectroscopic analyses of NMR and MS, as well as by comparing the reported NMR values in the literatures. Results Beminamycin C was isolated from the supernatant of Streptomyces sp. CPCC 203702. It showed significant anti-Mycobacterium tuberculosis activity with MIC value of 2 μg/ml.Conclusion Beminamycin C is obtained from the supematant ofStreptomyces sp. CPCC 203702 and its ^1H- and ^13C-NMR data are fully assigned for the first time. Beminamycin C shows remarkable anti-Mycobacterium tuberculosis activity which is never reported before.
出处 《中国医药生物技术》 2015年第4期351-355,共5页 Chinese Medicinal Biotechnology
基金 国家自然科学基金(81402835 81373452) 国家微生物资源平台(NIMR-2015-03) "重大新药创制"国家科技重大专项(2014ZX09201001-011)
关键词 链霉菌属 抗生素类 抗结核 伯尔尼霉素C Streptomyces Antibiotics, antitubercular Beminamycin C
  • 相关文献

参考文献16

二级参考文献67

  • 1Brien R J O, Nunn P P. The need for new drugs against tuberculosis obstacles, opportunities, and next steps [J].Am J Respir Crit Care Med,2001,163(5): 1055.
  • 2Trouiller P, Olliaro P. Drug developmen t output during 1975~96: what proportion for tropical diseases ? [J]. Int J Infect Dis,1999,3:61.
  • 3Tomioka H. Prospects for development of new antituberculous drugs [J]. Kekkaku, 2002,77 (8): 573.
  • 4Miyazaki E, Miyazaki M, Chen J M, et al. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis [J]. Antimicrob Agents Chemother, 1999,43: 85.
  • 5Fung-Tomc J, Minassian B, Kolek B, et al. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone,gatifloxacin [J]. J Antimicrob Chemother,2000,45:437.
  • 6Cynamon M H, Klemens S P, Sharpe C A, et al. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model [J]. Antimicrob Agents Chemother, 1999,43:1189.
  • 7Iseman M D. Tuberculosis therapy: past, present and future [J]. Eur Respir J,2002,20(Suppl 36):87.
  • 8Stover C K, Warrener P, Donald R, et al. A smallmolecule nitroimidazopyran drug candidate for the treatment of tuberculosis [J]. Nature, 2000,405: 962.
  • 9Yuan Y, Zhu Y, Crane D. The effect of oxygenated mycolic acid composition on cell wall function and macrophage growth in Mycobacterium tuberculosis [J]. Mol Microbiol, 1998,29:1449.
  • 10Ordway D, Viveiras M, Leandru C, et al. Clinical concentrations of thioridazine kill intracellular multidrugresistant Mycobacterium tuberculosis [J]. Antimicrob Agents Chemother , 2003,47: 971.

共引文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部